PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan Lauds Sorrento Therapeutics for Making Strides in the Global Biopharmaceutical Market - Based on its recent research, Frost & Sullivan presents Sorrento Therapeutics, Inc. (Sorrento Therapeutics) with the 2010 Global Biopharmaceutical Emerging Company of the Year Award
Frost & Sullivan Lauds Sorrento Therapeutics for Making Strides in the Global Biopharmaceutical Market

 

NewswireToday - /newswire/ - London, United Kingdom, 2010/06/10 - Based on its recent research, Frost & Sullivan presents Sorrento Therapeutics, Inc. (Sorrento Therapeutics) with the 2010 Global Biopharmaceutical Emerging Company of the Year Award.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The human monoclonal antibodies (mAbs) market is teeming with opportunities and was worth nearly $30 billion in 2009, growing at a healthy double digit rate of around 20 per cent. With an increasing number of mAbs attaining blockbuster status, pharmaceutical and biotech companies have been flocking to this market.

"In the competitive mAbs market, companies aim to be distinctive by developing enhanced technologies and processes," says Frost & Sullivan Industry Analyst Arun A. K. "Sorrento has constructed one of the largest mAbs libraries with industry-leading diversity, fully human and full-length mAbs that could be either commercialised or used for developing their own therapeutic candidates."

Another opportunity that has opened up for the Company is collaboration with leading industry participants. Since 2006 a number of deals were signed between a major pharmaceutical/biotech company and an antibody-centric biopharmaceutical company, illustrating the considerable opportunities for a proven mAb technology.

Sorrento Therapeutics has developed a ribonucleic acid (RNA) transcription-based amplification technology called STI Technology, which has competitive benefits over traditional PCR-based amplification methods for constructing antibody libraries. Unlike polymerase chain reaction (PCR), the STI Technology amplifies large numbers of different immunoglobulin variable domain sequences in parallel to generate human antibody libraries of vast diversity.

Sorrento Therapeutics also enables full mammalian display of mAbs and an efficient production system, thus, widens its commercial opportunities. Apart from these technical advantages, this technology can be easily adopted upon licensing without the Intellectual Property (IP)-related issues that are common with competing technologies.

"Further, Sorrento Therapeutics is taking great strides in enhancing its visibility," notes Arun. "It has hired an experienced business development professional from the antibody industry to promote and develop its business."

At present, the company is in talks with numerous enterprises to explore commercial opportunities. Besides this, it is committed to participating in major industry conferences to showcase and popularise its technology.

Each year, Frost & Sullivan presents this award to a company that has emerged as a significant participant in the industry. The Award is based on numerous factors including the company's business development, competitive strategy, and leadership within a particular Frost & Sullivan Industry Research Group (IRG). This company is perceived to exhibit outstanding management, high growth, and positive social and economic impact on local and national communities and customers. Exceptional customer service has been noted as crucial to success, coupled with the ability to combine technology and successful strategic initiatives. The Award recipient has also demonstrated superior market growth skills through significant gains in the market during the research period. This company has the exceptional know-how to take advantage of market changes through the execution of innovative strategies within the existing competitive landscape.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Sorrento Therapeutics
Sorrento Therapeutics, Inc. (sorrentotherapeutics.com) is a developmental stage biopharmaceutical company focused on discovery and development of human therapeutic antibodies for the treatment of a variety of disease conditions based on its proprietary technology platform. Established in 2006, Sorrento has invested in constructing human antibody libraries which will facilitate the rapid identification and isolation of highly specific mAbs for therapeutic purposes.

Sorrento Therapeutics Contact Information
Henry Ji, Ph.D., Chief Scientific Officer
Sorrento Therapeutics, Inc.
6042 Cornerstone Court West, Suite B
San Diego, CA 92121 U.S.A.
T: (858) 210-3701, F: (858) 210-3759
E: hji[.]sorrentotherapeutics.com.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Lauds Sorrento Therapeutics for Making Strides in the Global Biopharmaceutical Market

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Jasmine Malone 
+44 207 915 7869 jasmine.malone[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)